Skip to content

Study of BNCT on recurrent breast cancer

Pilot study of Boron Neutron Capture Therapy for recurrent breast cancer after radiotherapy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031220371
Enrollment
5
Registered
2022-10-07
Start date
2023-06-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer breast cancer

Interventions

Sponsors

Kurosaki Hiromasa
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Written consent for participation in this study has been obtained from the subject or a surrogate at the time consent is obtained. 2) The following patients with breast cancer Patients with confirmed recurrence within or at the margins of the chest radiotherapy field and one or more measurable lesions according to RECIST guidelines (version 1.1) Patients who have undergone radiotherapy for more than 6 months since their last radiotherapy treatment. Patients who are not adversely affected by withdrawal of chemotherapy (including molecular-targeted agents) for more than 4 weeks prior to BNCT treatment. Patients who are deemed capable of containing all active lesions within the irradiated area envisaged by BNCT Patients with the longest diameter of the entire target lesion of 15 cm or less Patients with lesions with a distance of 6 cm or less from the skin surface to the deepest part of the tumor Patients with no evidence of serious cardiac complications on resting 12-lead ECG

Exclusion criteria

Exclusion criteria: 1) Patients who have received more than 75 Gy of radiotherapy to the lesion area in the prior treatment of the target lesion. 2) Patients with active lesions/active overlapping cancers other than the target lesion (however, patients with distant metastases who show no tendency to enlarge and whose quality of life can be significantly improved by controlling locally recurrent lesions are not excluded) 3) Patients with measurable tumor skin exposure greater than 5 cm 4) Patients with NYHA cardiac function classification grade III or IV 5) Patients with pulmonary fibrosis or interstitial pneumonia

Design outcomes

Primary

MeasureTime frame
Safety: Acute adverse events for safety evaluation criteria

Secondary

MeasureTime frame
Efficacy: response rate, tumor shrinkage rate, progression-free survival, overall survival

Contacts

Public ContactHiromasa Kurosaki

Edogawa Hospital

h.kurosaki@edogawa.or.jp+81-3-3673-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026